<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cost-utility league table (example data for cost-effectiveness analyses)</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cost-utility league table (example data for cost-effectiveness analyses)</h1>
<div class="graphic"><div class="figure"><div class="ttl">Cost-utility league table (example data for cost-effectiveness analyses)</div><div class="cntnt"><table cellspacing="0"><colgroup width="60%"></colgroup><colgroup width="40%"></colgroup> <tbody> <tr class="divider_bottom"> <td colspan="2"><strong><em>For illustration purposes only</em></strong></td> </tr> <tr> <td class="subtitle1">Medical intervention</td> <td class="subtitle1">Incremental cost-effectiveness ratio<br/> ($ per discounted quality-adjusted life year gained unless indicated otherwise)</td> </tr> <tr> <td>No <span style="color: black;">prophylaxis versus intravenous saline for prevention of contrast-induced nephropathy in high risk patients<sup>[1]</sup></span></td> <td><span style="color: black;">No prophylaxis is cost-saving</span></td> </tr> <tr> <td><span style="color: black;">Publicly funded opiate use disorder treatment versus standard care<sup>[2]</sup></span></td> <td><span style="color: black;">Cost-saving</span></td> </tr> <tr> <td><span style="color: black;">Individualized glycemic control versus uniform control<sup>[3]</sup></span></td> <td><span style="color: black;">Cost-saving</span></td> </tr> <tr> <td>Novel oral anticoagulant versus warfarin<sup>[4]</sup></td> <td>Cost-saving to $2073 (assuming £1 = $1.4)</td> </tr> <tr> <td>Achieving UNAIDS 90-90-90 global HIV treatment target aims in South Africa over 10 years<sup>[5]</sup></td> <td>$1260 per life year gained</td> </tr> <tr> <td>Statin therapy for 1-year risk threshold of 7.5% versus 10% for primary prevention of cardiovascular disease<sup>[6]</sup></td> <td>$37,000</td> </tr> <tr> <td>Intensive versus standard blood pressure control in Systolic Blood Pressure Intervention Trial (SPRINT)<sup>[7]</sup></td> <td>$47,000</td> </tr> <tr> <td><span style="color: black;">Risk-targeted </span><span style="color: black;">low-dose CT versus NLST screening<sup>[8]</sup></span></td> <td><span style="color: black;">$53,000 to $75,000</span></td> </tr> <tr> <td>Statin-plus-PCSK9 inhibitor versus statin-plus-ezetimibe for atherosclerotic cardiovascular disease and LDL-C ≥70 mg/mL<sup>[9]</sup></td> <td>$450,000</td> </tr> <tr> <td>Initial biologic therapy versus triple therapy for active rheumatoid arthritis<sup>[10]</sup></td> <td>$521,520</td> </tr> </tbody></table></div><div class="graphic_footnotes"><font color="black">UNAIDS: Joint United Nations Programme on HIV/AIDS; CT: computed tomography; NLST: National Lung Screening Trial; PCSK9: proprotein convertase subtilisin/kexin type 9; LDL-C: low-density lipoprotein cholesterol.</font></div><div class="graphic_reference"><span style="COLOR: black">References: </span>
<ol>
<li><span style="COLOR: black">Nijssen EC, Rennenberg RJ, Nelemans PJ, et al. Prophylactic hydration to protect renal function from intravascular iodinated contrast material in patients at high risk of contrast-induced nephropathy (AMACING): A prospective, randomised, phase 3, controlled, open-label, non-inferiority trial. Lancet 2017; 389:1312.</span></li>
<li><span style="COLOR: black">Krebs E, Enns B, Evans E, et al. Cost-effectiveness of publicly funded treatment of opioid use disorder in California. Ann Intern Med 2018; 168:10.</span></li>
<li><span style="COLOR: black">Laiteerapong N, Cooper JM, Skandari MR, et al. Individualized glycemic control for U.S. adults with type 2 diabetes: A cost-effectiveness analysis. Ann Intern Med 2018; 168:170.</span></li>
<li><span style="COLOR: black">Lopez-Lopez JA, Sterne JAC, Thom HHZ, et al. Oral anticoagulants for prevention of stroke in atrial fibrillation: Systematic review, network meta-analysis, and cost effectiveness analysis. BMJ 2017; 359:j5058.</span></li>
<li><span style="COLOR: black">Walensky RP, Borre ED, Bekker LG, et al. The anticipated clinical and economic effects of 90-90-90 in South Africa. Ann of Intern Med 2016; 165:325.</span></li>
<li><span style="COLOR: black">Pandya A, Sy S, Cho S, et al. Cost-effectiveness of 10-year risk thresholds for initiation of statin therapy for primary prevention of cardiovascular disease. JAMA 2015; 314:142.</span></li>
<li><span style="COLOR: black">Bress AP, Bellows BK, King JB, et al. Cost-effectiveness of intensive versus standard blood-pressure control. N Engl J of Med 2017; 377:745.</span></li>
<li><span style="COLOR: black">Kumar V, Cohen JT, van Klaveren D, et al. Risk-targeted lung cancer screening: A cost-effectiveness analysis. Ann Intern Med 2018; 168:161.</span></li>
<li><span style="COLOR: black">Kazi DS, Penko J, Coxson PG, et al. Updated cost-effectiveness analysis of PCSK9 inhibitors based on the results of the FOURIER trial. JAMA 2017; 318:748.</span></li>
<li><span style="COLOR: black">Bansback N, Phibbs CS, Sun H, et al. Triple therapy versus biologic therapy for active rheumatoid arthritis: A cost-effectiveness analysis. Ann of Intern Med 2017; 167:8.</span></li></ol></div><div id="graphicVersion">Graphic 69531 Version 6.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
